Phase I and II clinical studies evaluating the safety, tolerability, pharmacokinetics, and efficacy of anti-Nogo-A antibodies (NG-101, AXER-204) in patients with spinal cord injury are currently underway [117]. The gene discussed is RTN4; the disease is spinal cord injury.